Belite Bio (BLTE) Tax Provisions (2023 - 2024)
Belite Bio's (BLTE) quarterly Tax Provisions came in at -$6.0 million in Q3 2024, down 599500.0% year-on-year from N/an in Q4 2023, and down 199.9% quarter-over-quarter from $6.0 million in Q1 2024.
Belite Bio (BLTE) Tax Provisions (2023 - 2024) Analysis & Trends
Belite Bio's Tax Provisions history runs 2 years deep, the most recent figure standing at -$6.0 million for Q3 2024.
- On a quarterly basis, Tax Provisions fell 599500.0% year-over-year to -$6.0 million in Q3 2024; TTM through Dec 2024 was $6000.0, a 99.93% decrease from a year earlier, with the FY2025 full-year figure at -$136000.0, down 2366.67% from the prior year.
- Tax Provisions declined to -$6.0 million in Q3 2024 per BLTE's latest filing, from $6.0 million in the prior quarter.
- Across five years, Tax Provisions topped out at $6.0 million in Q1 2023 and bottomed at -$6.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 125,146.46 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -859,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 31.86 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 221.50 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -60.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 15.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -5.99 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 3.00 Mn |
| Mar 31, 2023 | 6.00 Mn |